<DOC>
	<DOC>NCT00099281</DOC>
	<brief_summary>The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to anthracycline treatment. Stratification allocation will be within the following subgroups: 1. Prior cytotoxic treatment; 2. Estrogen receptor status; 3. ECOG performance status; 4. Number of cycles of chemotherapy.</brief_summary>
	<brief_title>DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer</brief_title>
	<detailed_description>Endpoints of the trial are as follows: primary: overall survival; secondary: response rate, progression free survival, toxicity, neurocognitive function.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histological proof of breast cancer Documented evidence of metastatic and/or recurrent breast cancer Presence of at least one bidimensional or unidimensional lesion ECOG status 0, 1 or 2 Quality of life</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Metastatic breast cancer</keyword>
</DOC>